4D Molecular Therapeutics, Inc. (FDMT) Investment Research Dashboard
About 4D Molecular Therapeutics, Inc. (FDMT) stock analysis
Get live FDMT stock price $10.07, comprehensive 4D Molecular Therapeutics, Inc. stock analysis, charts, news, sentiment, sector analysis, and expert forecast. Real-time FDMT stock data and investment insights.
Loading chart data...
Investment Score
A systematic tri-factor framework (valuation, quality, momentum) using trailing twelve-month fundamentals and current price momentum—aligned with the full investment score dashboard.
Score unavailable for this asset.
0-39
Defensive posture
40-54
Mixed / wait for confirmation
55-69
Constructive setup
70-100
Attractive zone
Total Score
Value
Cheapness vs fundamentals and cash generation
Quality
Durability of profitability and balance sheet
Momentum
Price trend strength and persistence
Company Overview
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a tri...
Company Information
- CEO
- David H. Kirn
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 196
Contact Information
- Address
- 5858 Horton Street
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Higher growth potential with elevated volatility (Beta: 2.69)
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for 4D Molecular Therapeutics, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for 4D Molecular Therapeutics, Inc.
- ⚠Investors should consider how 4D Molecular Therapeutics, Inc. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
526.42M
P/E Ratio (TTM)
-3.92
Beta
2.69
Data Sources & Methodology
Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.
Healthcare (1D)
77/100 ⭐⭐⭐⭐⭐
- Overall
- +0.3%
- NYSE
- +0.7%
- NASDAQ
- -0.2%
| Sector | 1D | 1W | 1M | P/E | Score |
|---|---|---|---|---|---|
| Financial Services | +0.3% | +1.5% | +2.2% | 19.1 | 82/100⭐⭐⭐⭐⭐ |
| Healthcare | +0.3% | +2.7% | +1.5% | 23.5 | 77/100⭐⭐⭐⭐⭐ |
| Real Estate | +1.8% | +4.6% | +0.7% | 29.8 | 72/100⭐⭐⭐⭐⭐ |
| Communication Services | +0.7% | -2.1% | +2.2% | 21.8 | 70/100⭐⭐⭐⭐⭐ |
| Basic Materials | +0.9% | +2.0% | -0.3% | 25.0 | 60/100⭐⭐⭐⭐ |
| Consumer Defensive | +0.8% | +1.0% | -0.2% | 28.7 | 55/100⭐⭐⭐⭐ |
| Utilities | -0.7% | +2.5% | -1.9% | 25.2 | 49/100⭐⭐⭐ |
| Energy | -0.2% | -0.4% | -2.4% | 19.6 | 42/100⭐⭐⭐ |
| Consumer Cyclical | +0.3% | -1.6% | -4.0% | 43.3 | 17/100⭐ |
| Industrials | -0.5% | -0.1% | -8.9% | 30.4 | 15/100⭐ |
| Technology | -1.6% | -0.8% | -5.3% | 42.2 | 12/100⭐ |
Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-07-27.